Biblioteca Hospital 12 de Octubre
Vista normal Vista MARC Vista ISBD

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. [artículo]

Por: Martínez López, Joaquín [Hematología y Hemoterapia] | López Anglada, Lucía [Hematología y Hemoterapia] | Cedena Romero, María Teresa [Hematología] | Sáez Gómez, María Auxiliadora [Hematología y Hemoterapia] | Rapado Martínez, Inmaculada [Instituto de Investigación i+12] | Cueto Felgueroso, Cecilia [Hematología y Hemoterapia] | Lahuerta Palacios, Juan José [Hematología y Hemoterapia].
Colaborador(es): Servicio de Hematología y Hemoterapia | Instituto de Investigación imas12.
Tipo de material: materialTypeLabelArtículoEditor: Blood, 2015Descripción: 126(7):858-62.Recursos en línea: Solicitar documento Resumen: Stringent complete response (sCR) criteria are used in multiple myeloma as a deeper response category compared with CR, but prospective validation is lacking, it is not always clear how evaluation of clonality is performed, and is it not known what the relative clinical influence is of the serum free light chain ratio (sFLCr) and bone marrow (BM) clonality to define more sCR. To clarify this controversy, we focused on 94 patients that reached CR, of which 69 (73%) also fulfilled the sCR criteria. Patients with sCR displayed slightly longer time to progression (median, 62 vs 53 months, respectively; P = .31). On analyzing this contribution to the prognosis of sFLCr or clonality, it was found that the sFLCr does not identify patients in CR at distinct risk; by contrast, low-sensitive multiparametric flow cytometry (MFC) immunophenotyping (2 colors), which is equivalent to immunohistochemistry, identifies a small number of patients (5 cases) with high residual tumor burden and dismal outcome; nevertheless, using traditional 4-color MFC, persistent clonal BM disease was detectable in 36% of patients, who, compared with minimal residual disease-negative cases, had a significantly inferior outcome. These results show that the current definition of sCR should be revised.
Etiquetas de esta biblioteca: No hay etiquetas de esta biblioteca para este título. Ingresar para agregar etiquetas.
    valoración media: 0.0 (0 votos)

Formato Vancouver:
Martínez López J, Paiva B, López Anglada L, Mateos MV, Cedena T, Vidríales MB et al; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood. 2015 Aug 13;126(7):858-62.

PMID: 26089396
PMC4543912

Contiene 21 referencias

Stringent complete response (sCR) criteria are used in multiple myeloma as a deeper response category compared with CR, but prospective validation is lacking, it is not always clear how evaluation of clonality is performed, and is it not known what the relative clinical influence is of the serum free light chain ratio (sFLCr) and bone marrow (BM) clonality to define more sCR. To clarify this controversy, we focused on 94 patients that reached CR, of which 69 (73%) also fulfilled the sCR criteria. Patients with sCR displayed slightly longer time to progression (median, 62 vs 53 months, respectively; P = .31). On analyzing this contribution to the prognosis of sFLCr or clonality, it was found that the sFLCr does not identify patients in CR at distinct risk; by contrast, low-sensitive multiparametric flow cytometry (MFC) immunophenotyping (2 colors), which is equivalent to immunohistochemistry, identifies a small number of patients (5 cases) with high residual tumor burden and dismal outcome; nevertheless, using traditional 4-color MFC, persistent clonal BM disease was detectable in 36% of patients, who, compared with minimal residual disease-negative cases, had a significantly inferior outcome. These results show that the current definition of sCR should be revised.

No hay comentarios para este ejemplar.

Ingresar a su cuenta para colocar un comentario.

Con tecnología Koha